Rhythm Pharmaceuticals reported total revenues of $223.5 million for the nine months ended September 30, 2026, a significant increase from $132.5 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $146.3 million due to increased selling, general, and administrative expenses and research and development costs.
Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, a 29% sequential increase driven by the strong U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company also secured a five-year term loan facility for up to $750 million and announced plans to advance bivamelagon into pivotal development for Prader-Willi syndrome.
Term
Q3 2026
“Rhythm continues to make strong progress in bringing IMCIVREE® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
“We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals